Real world utilisation of doravirine among people living with human immunodeficiency virus in England (DRIVE-REAL).
Charlotte O'HalloranYvonne GilleeceSuki LeungVeronica CanutoConnor McAlpineSophie A RossClaire NorcrossStuart GaffneyNipur SianiWilliam HickeyAdam MooreOlivera Rajkovic-HooleyAna MilinkovicPublished in: International journal of STD & AIDS (2023)
Individuals initiating doravirine in this cohort are predominantly treatment-experienced white middle-aged males, with a high frequency of comorbidities and co-medication. The majority of individuals at 6 months remained on doravirine and maintained or achieved HIV viral suppression. This study provides epidemiologic characteristics that can inform clinical care and subsequent hypothesis-testing studies.
Keyphrases
- human immunodeficiency virus
- high frequency
- antiretroviral therapy
- hepatitis c virus
- hiv infected
- middle aged
- transcranial magnetic stimulation
- healthcare
- hiv positive
- hiv aids
- palliative care
- sars cov
- hiv testing
- quality improvement
- adverse drug
- african american
- emergency department
- combination therapy
- health insurance